Patient discomfort with common test options like colonoscopy or stool-based tests continue to drive high non-compliance with recommended CRC screening guidelines, resulting in most cancers being detected in its’ late stages where its’ least curable. Currently approximately 40% of qualified patients in the U.S. do not comply with colorectal cancer screening guidelines.
About Colorectal Cancer
Colorectal cancer (CRC) occurs when cells lining the colon or rectum begin to divide rapidly and form small tumors or premalignant polyps. Though usually benign, some of these polyps may become malignant or cancerous over time. If these cancerous cells grow into the wall of the colon or rectum, the cancer can spread to other organs in a process called “metastasis.” Colorectal Cancer (CRC) is one of the biggest killers in the U.S. claiming more than 50,000 lives per year¹. CRC is the most preventable and treatable form of cancer when detected early. If diagnosed at an early stage, the five-year survival is 90%.
ColonSentry® is an advanced, blood-based molecular diagnostic that measures the expression of seven gene biomarkers (signatures) in the blood that are early warning signs of colorectal cancer(CRC).